LOW-DOSE RADIATION EX VIVO REPROGRAMMED/ACTIVATED CAR T CELLS TARGETING B7-H3 ON PROSTATE CANCER.

$1,249,800FY2021Defense Health AgencyDOD

The General Hospital Corporation

Investigators